United Therapeutics (UTHR) Rating Lowered to Hold at BidaskClub

United Therapeutics (NASDAQ:UTHR) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

UTHR has been the topic of a number of other reports. ValuEngine downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Barclays dropped their price target on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating on the stock in a research report on Friday, March 1st. Cowen set a $106.00 price target on shares of United Therapeutics and gave the stock a “hold” rating in a research report on Thursday, November 15th. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b-” rating in a research report on Monday, February 11th. Finally, Oppenheimer set a $160.00 price target on shares of United Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. United Therapeutics has a consensus rating of “Hold” and an average price target of $132.67.

Shares of NASDAQ:UTHR opened at $117.03 on Wednesday. The stock has a market capitalization of $5.07 billion, a P/E ratio of 8.74, a PEG ratio of -1.71 and a beta of 1.11. United Therapeutics has a fifty-two week low of $100.06 and a fifty-two week high of $130.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.03 and a current ratio of 6.39.



United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.19 by ($0.71). The firm had revenue of $381.40 million during the quarter, compared to the consensus estimate of $355.81 million. United Therapeutics had a net margin of 36.20% and a return on equity of 22.63%. The company’s revenue for the quarter was down 17.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.89 earnings per share. On average, research analysts expect that United Therapeutics will post 9.28 earnings per share for the current fiscal year.

In related news, CEO Martine A. Rothblatt sold 7,054 shares of the business’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $113.16, for a total transaction of $798,230.64. Following the transaction, the chief executive officer now directly owns 7,195 shares of the company’s stock, valued at $814,186.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Patusky sold 3,370 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $110.75, for a total transaction of $373,227.50. The disclosure for this sale can be found here. Insiders sold a total of 102,527 shares of company stock worth $11,695,041 in the last ninety days. Corporate insiders own 8.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Oregon Public Employees Retirement Fund grew its position in United Therapeutics by 10,537.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 3,517,845 shares in the last quarter. Norges Bank purchased a new position in United Therapeutics during the fourth quarter valued at approximately $54,233,000. Renaissance Technologies LLC grew its position in United Therapeutics by 24.9% during the third quarter. Renaissance Technologies LLC now owns 1,944,078 shares of the biotechnology company’s stock valued at $248,609,000 after purchasing an additional 387,878 shares in the last quarter. AQR Capital Management LLC grew its position in United Therapeutics by 11.3% during the third quarter. AQR Capital Management LLC now owns 2,327,367 shares of the biotechnology company’s stock valued at $297,624,000 after purchasing an additional 235,459 shares in the last quarter. Finally, First Trust Advisors LP grew its position in United Therapeutics by 13.6% during the fourth quarter. First Trust Advisors LP now owns 1,196,804 shares of the biotechnology company’s stock valued at $130,332,000 after purchasing an additional 143,235 shares in the last quarter. 97.22% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: Purposes and Functions of the Federal Reserve

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.